RxDoctor Payments Data

Elicia Roos, DO

Family Medicine · Ponte Vedra, FLNPI 1710274642

Payments from drug & device makers

$3,530in general payments, 2019–2025

Across 161 payments — averaging $21.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$473
  • AbbVie$346
  • Novo Nordisk$323
  • Kerecis Limited$317
  • Lilly USA, LLC$282
  • AstraZeneca$268
  • plus $2K from 20 others

What the payments were for

  • Food & beverage$3,10888%
  • Education$42212%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,530 in reported general payments places this provider in the 80th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$116,499
Medicare patients
303
Services billed
1,284

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide71$79,716
EliquisApixaban52$67,937
OzempicSemaglutide58$62,439
TrulicityDulaglutide30$38,431
JardianceEmpagliflozin32$31,057
Repatha SureclickEvolocumab19$21,987
Breo ElliptaFluticasone/Vilanterol25$10,505
Tresiba Flextouch U-100Insulin Degludec23$7,184
SynthroidLevothyroxine Sodium68$5,563
VyvanseLisdexamfetamine Dimesylate13$4,970
SymbicortBudesonide/Formoterol Fumarate19$4,474
Levothyroxine Sodium377$3,508
Liothyronine Sodium62$3,440
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine61$2,772
Rosuvastatin Calcium184$2,362

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$282$118,147101 claims
PfizerEliquis$473$67,93752 claims
Novo NordiskOzempic$323$62,43958 claims
Boehringer IngelheimJardiance$253$31,05732 claims
GSKBreo Ellipta$195$10,50525 claims
AbbVieSynthroid$346$5,56368 claims
AstraZenecaSymbicort$268$4,47419 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 7,282 family medicine providers in Florida.

Other family medicine in Ponte Vedra

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →